| |
 |
| Conference on Private Equity & Lifescience - 14-15 November 2006 |
|
|
|
|
| |
 |
|
|
| |
Date: 14th-15th November
Venue: ITC Grand Maratha Sheraton, Mumbai, India. |
| |
| |
| |
In case you missed the conference, you now have the best next thing by ordering the DVD package of the conference for Rs. 50,000 or USD 2400, including taxes and shipping.
The Indian Venture Capital Journal has organised its first Private Equity centric conference on Lifesciences, including Pharmaceutical, Biotechnology and Healthcare sectors, being held in Mumbai at the ITC Grand Maratha Sheraton on the 14 th and the 15 th of November, 2006. Featuring erudite speakers who are active practitioners in the industry, this event is an interactive knowledge dissemination platform which will throw light on the changing Lifesciences milieu and address the industry's imminent challenges with possible solutions. The conference will explore the myriad of opportunities that are evolving and touch areas of regulatory issues; legal and tax perspectives; and nuances of optimum deal structuring within the parameters in this space. From Private Equity being a trickle a few years ago it is turning into a raging river with pharma being one of the biggest deal pullers.
The package includes a complete set of 12 menu-driven high-resolution DVDs covering the entire conference, from the opening session of the first day to the closing session of the second day. You also get the database of all the attendees (in excel format) and the power point presentations of each session. |
| |
| |
|
| |
| |
|
| |
| |
Overview
IVCJ is proud to bring to you the first VC&PE centric forum in India , purely focused on the exciting Lifesciences industry. Private Equity has been a noteworthy catalyst of entrepreneurial activity in the pharmaceutical industry. Existing and would-be entrepreneurs and technocrats seriously considering the risk capital route need to understand the expectations of the VC&PE community and bring forward well thought-out business strategies to their table for consideration. On the other side of the coin, the VC&PE community and investors need to understand the returns and challenges of the Lifesciences industry to be able to hone in to the right deals. This exclusive two-day conference, the first of its kind in India, provides a platform for investors and industry players alike to discuss and plan their strategies around a totally new risk and returns milieu. IVCJ aims to bring out an absolute picture of the VC&PE activity taking place in all the 3 sections of lifesciences, namely pharmaceuticals, biotechnology and healthcare . It also aims to bring key decision makers from the of VC&PE and Lifesciences industries to facilitate discussion on key issues and create a conducive networking environment.
Private Equity investments have also seen record growth of about 85% from $1.1 billion in 2004 to $ 2.03 billion in 2005. The VC&PE community's buoyant confidence in this sector was evident by the fact that the LifeSciences sector emerged as one of the leading recipients of funds accounting for 18% share of all VC&PE investments in 2005.
The Lifesciences Sector is a key growth driver of India 's economy and the year 2005 will go down as the year of renaissance for the Lifesciences, bringing fresh vitality and vigour to the industry. Compliance with the TRIPS mandate at the beginning of 2005 has revolutionized the very identity of Indian pharmaceuticals and thrust it down the path of innovation. Today, India Inc. has become an integral part of the global Lifesciences market with a growing share in this space. Cost arbitrage and high quality capabilities are shifting global pharmaceutical attention to India, which could soon make it the pharmaceutical manufacturing hub of the world. Accelerated inroads into the biotech space and a healthcare industry on the verge of a boom, are attracting soaring global awareness presenting a plethora of opportunities. |
| |
| |
| LIST OF SPEAKERS* |
| |
| Ajay K. Kapur, |
SIDBI Venture Capital Company Limited |
| Akhil Awasthi, |
Baring Private Equity Partners ( India) Ltd. |
| Alok Gupta, |
Yes Bank |
| Ameera Shah |
Metropolis Health Services (I) Pvt. Ltd |
| Ashwin Naik |
Vaatsalya Healthcare |
| Ashwin Naik |
Vaatsalya Healthcare |
| Balaji Iyengar Durai, |
Manipal Acunova |
| Dinesh Dua, |
Wockhardt Limited |
| Ganesh Lakshmanan, |
Modern Medicare |
| Gowree Gokhale, |
Nishith Desai Associates |
| Jaisingh Dhumal, |
ICICI Bank |
| Lisa Conte, |
NOPA Pharmaceuticals |
| Luis Miranda, |
IDFC Private Equity Company Limited |
| Mark Yacura, |
Buchanan Ingersoll & Rooney PC |
| Milind Antani, |
Nishith Desai Associates |
| Naryanan Suresh, |
Bio-Spectrum |
| Nimish Parekh, |
UnitedHealthCare – India Group Companies |
| Nishith Desai, |
Nishith Desai Associates |
| Nitin Deshmukh, |
Kotak Mahindra Bank Limited |
| R.B. Smarta, |
Interlink Consultancy Pvt Ltd. |
| Rahul Shah, |
IL&FS Investment Managers Limited |
| Rajiv Shukla, |
Advinus Therapeutics |
| Rajnish Rastogi, |
IL&FS Investment Managers Limited |
| Ranu Vohra, |
Avendus Advisors Private Limited |
| Ravi Challu, |
market RX India |
| Sajai Singh, |
J. Sagar & Associates |
| Sanjeev Krishnan, |
Global Environment Fund |
| Sarath Naru, |
APIDCVC |
| Shiraz Bugwadia, |
Avendus Advisors Private Limited |
| Simon Best, |
Ardana Biosciences |
| Srinivasa Aluri Rao, |
ICICI Venture Funds Management Company Limited |
| Subash Lingareddy, |
Ocimum |
| Subinder Khurana, |
market RX India |
| Sudhir Nair, |
CRISIL Research |
| Sunaina Murthy , |
India Healthcare Advisors |
| Suryanarayanan, |
Lifetime Healthcare Pvt Ltd |
| Terry Rea, |
Buchanan Ingersoll & Rooney PC |
| Utpal Oza, |
KPMG |
| Venkat Jasti, |
Suven Lifesciences Limited |
| Vishal Bali, |
Wockhardt Hospitals Limited |
| Vishnu Varshney, |
GVFL Limited |
|
| |
| |
| |
| ROGRAMME SCHEDULE*
|
| |
| Download Latest Speakers & Programme Details |
| |
|
|
|
Registration and Breakfast |
Panel 1 |
Valuation and Due Diligence Dynamics in the Lifesciences |
|
Private Equity and Lifesciences: Market Update |
|
Panel 2 |
The State of the Indian Healthcare Industry |
|
Building Hospitals: Is it the next gold rush? How are we gearing up our Hospitals to handle Medical-Tourism? Is demand for more and better hospitals being spurred by the growing middleclass and awareness? New technology in Hospital informatics. Need for fresh Management thinking, more corporate approach with sharper professionalism. |
|
Diagnostics and Pathology: Who is riding the new outsourcing wave to hit India ? The diagnostics and pathology market is currently 2.5 % of the overall healthcare delivery market with 40,000 independent pathology labs in the country. Currently valued at US $864 million, the diagnostics and pathology laboratory-testing business is growing at a CAGR of 20 percent. Overloaded infrastructure and limited skilled manpower the world over has translated into the new outsourcing wave to hit India - high-end laboratory and diagnostic testing.. What are we doing to to build up this potential? |
|
CASE STUDY: ICICI Venture & METROPOLIS |
|
CASE STUDY: Dr. LAL LABS |
|
Q&A Session |
|
Networking Session - Tea/Coffee Break |
|
Panel 3 |
Building a Healthcare Business based on Specialisation, Presence & Scale: Challenges and Opportunities? |
|
Hospitals are key part of India 's Social Infrastructure Development: Are institutions geared up to take the challenge of bridging the investment gap? |
|
Dynamics of Venture Capital for SMEs in Lifesciences |
|
Pharma Retailing: A Win-Win development? Can organised pharma retailing foster Prescription control; help propagate cost-effective health insurance and improve the cost structures within the industry? Is pharma or total healthcare retailing an opportunity for PE investments? |
|
Regulatory Boundaries and their Impact. |
|
Optimal Deal Structuring from Tax and Legal perspectives. |
| |
Q&A Session |
Networking Session - Lunch
|
|
Panel 4 |
Marketing and Branding of the Indian healthcare industry: What are the perils and promises for the healthcare industry? How can marketing and branding of the Indian healthcare industry? How important are International accreditations? How can one promote Medical-Tourism? Should hospitals turn towards specialisation? What opportunities does the emergence integrated healthcare services present for PE investment? |
|
How is Insurance changing the Face of Indian Healthcare? |
|
The Successes and Failures of the Western model of Managed Healthcare? Differences between American and European models, and lessons to be learnt for India . |
|
Can the western models of Managed Healthcare be the model for the Indian masses? |
|
Scope for Collaboration between the Indian Healthcare and Insurance majors. What opportunity does this present to PE Players? |
|
What role can M&A play in a fragmented healthcare industry? |
|
Smoldering Opportunity in Medical devices - India primarily manufactures only low-tech devices whereas the demand for hi-tech products is 80% of the overall demand for medical devices in India . A staggering 90% of the demand is fulfilled through imports. What are the growth prospects of this industry in India and what are the new challenges and threats for medical device investing? |
| |
Q&A Session |
Networking Session - Tea/Coffee Break
|
|
Panel 5 |
Alternative Funding Models for Lifescience companies. |
|
Innovative models for financing R&D. |
|
Mezzanine, Senior Debt and Acquisition Financing |
|
What role can M&A play in a fragmented healthcare industry? |
| |
Q&A Session |
|
Cocktail - Dickenson Associates |
|
Gala Dinner |
|
| |
| |
|
|
|
Registration and Breakfast |
Panel 1 |
Opening Note |
| |
What do PEs look for when investing in the lifesciences industry? What are the main parameters of the scorecard that helps PEs decide whether an investment is a ‘go' or ‘no-go'? |
| |
Q&A Session |
|
Networking Session - Tea/Coffee Break |
|
Panel 2 |
The shifting visage of the Indian Pharmaceutical Industry. How is the Industry Maturing? Transition from short term stakeholders return approach to structuring long term value through innovation in a TRIPs compliant milieu. Examining the future prospects of the industry and where it is going. What area is going to boom and what will die out? What kind of a business model is evolving for pharma companies? How is the R&D model changing? |
|
Addressing the Industry's Imminent Challenges: The New Drug Policy - What does this mean for the industry? Many companies have stopped manufacturing drugs that had been around for a long time and were cheaper than newer drugs. Industry sources say that 30 out of 75 drugs (40%) currently under DPCO are out of production or drastically reduced. Will this have any adverse affect on the export growth story that many pharma companies are charting? |
| Addressing the Industry's Imminent Challenges: The New Drug Policy - Impacts and Adjustments pharma companies will have to contend with. How does the current policy affect PE thinking? |
| Venture Capital for SMEs in Life Sciences: What challenges do SME in this space face? What value-adds can VCs bring to the table? |
Going the M&A way in the Pharma Space: There has been an unprecedented sharp rise in the number of cross-border deals over the past year as Indian companies have been on a worldwide acquisition spree,leading to a three-fold rise in overseas buyouts by Indian companies escalating up to US $4.5 billion from US $1.7 billion in the year 2004.
What are the drivers for cross border acquisitions? How should an Indian pharama company incorporate M&A into tactical growth plans.
• Recognizing when acquisition is the best option for growth strategy • Honing in to what you need • Structuring, valuation and getting the deal going • Managing mergers and realizing synergies • Growing role of PEs in M&A. Examining the Private Equity opportunities in India : What prospects does the market offer? |
| Regulatory and tax issues: DPCO and the New Drug Policy; Nuances of the TRIPs milieu; Growing importance of efficient Intellectual Property Management; Ramification for the Entrepreneur and PE; Optimal deal structures from a legal and tax perspective within the regulatory parameters. What policies are being implemented to promote the generic market in India ? |
|
Q&A Session |
|
Networking Session - Lunch |
|
Panel 3 |
Generics model: Hazard or Opportunity ? India is now moving towards playing the lead role in the global generics story, building up to be the global generics hub. With nearly $40bn worth of drugs to go off patent in the next four years, Indian generic drug manufacturers are expected to be the major players. Is the generics business model an opportunity or hazard for pharma? The generics market is defined by low-margins and with pricing pressures worldwide, what are the new survival strategies? Companies big on APIs and formulations and branded generics can compete. Explore the growing importance of using efficient marketing, branding and sales strategies in order to capitalize on customer loyalty and succeed in a crowded market. What are the solution for Competing Successfully in the Generics space? What pro-active generic strategies can a pharma player employ? |
|
Can India deliver the next Blockbuster drug? An industry player's perspective. |
|
What role can a PE play in commercialising NCEs? A PE's perspective. |
|
Case Study: ICICI Venture & Perlecan |
|
Clinical and Preclinical Trials: Can PEs make hay as India becomes the research lab of the world? With the global outsourcing market in pre-clinical and clinical research exceeding US$13 billion in 2005, India is emerging as the research lab of the world. Its value proposition in clinical research is undeniable for many reasons. How are we coping with the enormous challenges for the existing medical manpower and healthcare infrastructure, due to the rapid growth in this market? Competencies in clinical research has become a core strength of the Indian phrma landscape. As more and more international companies are looking at India as a preferred destination, what opportunities exist for PEs and industry players? |
| Case Study: IL&FS & Manipal Acunova |
| What opportunity does CRAMS Offer? An Industry perspective. The global pharmaceutical market is estimated to represent a $48 billion opportunity for India by 2007, in terms of manufacturing outsourcing of APIs and intermediates; development outsourcing-conducting preclinical and clinical trials; and customized chemistry services-contract research services for compounds pre-launch. Are we equipped to become the manufacturing hub of the world? Key winning aspects to give a Competitive Edge. How do we gear up? |
| Q&A Session |
|
Panel 4 |
Networking Session - Tea/Coffee Break |
|
Indian Biotech is only 1.7% of the global Biotech market! What are the growth dynamics and challenges faced in India ?
As risk associated with investments in this industry is high, private equity, as a class of funding, is crucial to escalate the development of the Indian Biotech sector in the same vein as it served as a catalyst for the biotech industries in Europe and the US . Equally, existing and would-be entrepreneurs and technocrats need to seriously consider the risk capital route and bring forward well thought-out business strategies to the table of private equity players for consideration. With timely indications of more enthusiasm from Private Equity players, the Indian Biotech Industry has the potential to scale into a force to reckon with over the medium to long term. |
|
Wockhardt: Experiences of a pioneer in scaling a biotech business. |
|
Industry-Academia interaction – How are we Strengthening the Backbone of the Biotech industry?
The Industry needs for a more organised nation-wide framework that fosters logical exchange of knowledge and information, networking. What are we doing to overhaul the life-sciences curricula at both the under-graduate and post-graduate levels to reflect current progress in the field and be equipped to deliver the needs of the industry? |
|
Legal, Regulatory and tax issues
The proposed National Indian biotech strategy is targeting $5 billion in revenues and creating 1 million jobs by 2010. How is the Government's policies facilitating the Industry to achieve this target? |
|
Bioinformatics – What prospects for investment does this new sunrise sector offer?
India 's entry into the product patent regime in 2005 has heightened the bioinformatics sector in 2004-05. Today, the aim of every company in this space is find the precise drug for the right patient in the least possible time at minimal cost, and a strong bioinformatics foundation can make that happen. It is being suggested that with the entry of software firms in the area of life sciences, the cost of drug development may go down by at least 40%. As India positions itself as a global hub for bioinformatics, does this new sunrise sector present exciting prospects for investment and growth to PE investors? |
Q&A Session |
|
Closing Session |
|
| |
| |
| |
| |
Disclaimer:
This schedule is subject to change & confirmation from all the participant. Dickenson reserves the right to make modifications anytime before the event. |
| |
|
|
|
